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Abstract Sialic acids comprise a family of terminal sugars
essential for a variety of biological recognition systems. UDP-N-
acetylglucosamine 2-epimerase catalyzes the first step of their
biosynthesis. Periodate-oxidized UDP-N-acetylglucosamine,
namely 2P,3P-dialdehydo-UDP-K-D-N-acetylglucosamine, was
found to be an effective inhibitor of this enzyme, compared
with the periodate oxidation products of compounds such as
UDP, uridine or methyl riboside. It bound covalently to amino
acids in the active site causing an irreversible inhibition. This
compound may therefore represent a basis for the synthesis of
potent inhibitors of UDP-N-acetylglucosamine 2-epimerase and,
as a consequence, of the biosynthesis of sialic acids. % 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Sialic acids are terminal sugars of the oligosaccharide
chains in glycoconjugates. They are well suited to their role
as molecular determinants of speci¢c biological processes such
as cellular adhesion [1], formation or masking of recognition
determinants [2,3], and stabilization of the structure of glyco-
proteins [4]. Also, cell surface sialylation has been implicated
in the tumorigenicity and metastatic behavior of malignant
cells [5,6].
N-Acetylneuraminic acid (Neu5Ac), the most common nat-
urally occurring sialic acid, is the biosynthetic precursor of
this group of compounds. In mammals biosynthesis of Neu5-
Ac is initiated by UDP-N-acetylglucosamine 2-epimerase
(UDP-GlcNAc 2-epimerase), followed by phosphorylation of
the released N-acetylmannosamine by N-acetylmannosamine
kinase (ManNAc kinase). In mammalian cells both enzymes
are combined in a single bifunctional enzyme, UDP-GlcNAc
2-epimerase/ManNAc kinase [7,8]. Neu5Ac is then formed by
Neu5Ac 9-phosphate synthase [9,10] and consecutive release
of the phosphate moiety. CMP-Neu5Ac synthase catalyzes the
¢nal step of the pathway, the activation of Neu5Ac in the
nucleus [11,12]. CMP-Neu5Ac then serves as substrate of
the sialyltransferases in glycoconjugate biosynthesis [13].
Neu5Ac biosynthesis is regulated by feedback inhibition of
UDP-GlcNAc 2-epimerase by CMP-Neu5Ac [14]. Strongly
positive cooperative binding of the inhibitor connects Neu5Ac
biosynthesis e¡ectively to the consumption of sialic acids in
glycoconjugate synthesis [7]. Loss of UDP-GlcNAc 2-epimer-
ase leads to a drastic decrease of cellular sialylation, in£uenc-
ing several sialic acid-dependent functions [15]. Therefore,
inhibition of UDP-GlcNAc 2-epimerase activity is an
appropriate means of regulating cell surface sialylation. Zeit-
ler et al. [16] showed that UDP-GlcNAc 2-epimerase activity
was sensitive to metal ions, but this inhibitory e¡ect was
mainly attributed to an oxidation of cysteine residues in the
active site. Here we present the ¢rst potent in vitro inhibitor
of the enzyme, 2P,3P-dialdehydo-UDP-K-D-N-acetylglucos-
amine (oxidized UDP-GlcNAc, o-UDP-GlcNAc), which
may serve as a basis for the chemical synthesis of further
inhibitors.
2. Materials and methods
2.1. Materials
All chemicals and enzymes, if not otherwise indicated, were from
Sigma (Deisenhofen, Germany).
2.2. Chemical synthesis of o-UDP-GlcNAc, o-uridine, methyl o-riboside
and r-UDP-GlcNAc
o-UDP-GlcNAc was synthesized following the procedure of Prehm
[17]. 100 mg (154 Wmol) UDP-GlcNAc was dissolved in 1 ml 40 mM
Na2HPO4, pH 6.8. One equivalent of NaIO4 was added and allowed
to react for 1 h at 0‡C with continuous stirring. The reaction was
stopped by addition of 10 Wl glycerol. The products were desalted on a
Bio-Gel P2 column (Pharmacia, Freiburg, Germany) using water as
eluent. The eluate was lyophilized, dissolved in ethyl acetate/metha-
nol/water (3:2:1) and applied to a silica gel column. The compounds
were eluted with ethyl acetate/methanol/water (3:2:1) and fractions
were collected and checked by thin-layer chromatography. Fractions
containing o-UDP-GlcNAc were pooled, the solvent was evaporated
and 85.7 mg (132 Wmol, 86%) of the white foam was analyzed by
nuclear magnetic resonance (NMR; Bruker DRX 600; Bruker,
Rheinstetten, Germany), mass spectrometry (Kompact MALDI
2-Spectrometer; Kratos Analytical, Hofheim, Germany) and elemen-
tal analysis (CHN-analysator; Heraeus, Hofheim, Germany).
o-Uridine and methyl o-riboside were synthesized in a similar man-
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ner with the exception that the periodate oxidation was performed at
room temperature for 2 h, o-uridine was eluted with ethyl acetate/
methanol (10:1), and methyl o-riboside was eluted with ethyl acetate
from the silica gel column. 56 mg white foam (231 Wmol, 56%)
o-uridine and 24 mg (148 Wmol, 49%) methyl o-riboside were analyzed
by 1H NMR and mass spectrometry. o-UDP, o-ADP and o-GDP
were obtained from Sigma.
Reduced UDP-GlcNAc (r-UDP-GlcNAc) was synthesized by re-
duction of o-UDP-GlcNAc with sodium borohydride. 40 Wmol
o-UDP-GlcNAc was dissolved in 1.5 ml water. 400 mg sodium boro-
hydride was added and the reaction was performed overnight at room
temperature. The progress of the reaction was followed by TLC. The
products were desalted on a Bio-Gel P2 column and puri¢ed by silica
gel chromatography as described above for o-UDP-GlcNAc. 8.5 mg
(13 Wmol, 33%) of the white foam was analyzed by NMR.
2.2.1. Chemical analysis.
o-UDP-GlcNAc
TLC (Ethyl acetate/methanol/water 3:2:1): Rf = 0.32
1H NMR (400 MHz, D2O): N (ppm)=2.09 (s, 3H, Ac), 3.50^4.02
(m, 9H, H-4P, H-5Pa, H-5Pb, 7 H Glc), 5.18^5.68 (m, 2H, H-2P, H-3P),
5.88^6.01 (m, 2H, H-1P, H-5), 7.83^7.95 (m, 1H, H-6)
31P NMR (162 MHz, D2O): N (ppm)=310.6 (mc, 1P, KP), 312.4
(d, 1P, J=17 Hz, LP)
MALDI-MS: [M+Hþ] = 650.7
Elemental analysis calculated for C17H23N3O17P2Na2U4 H2O
(721,31): N, 5.82; C, 28.31; H, 4.33. Found: N, 5.69; C, 28.62; H,
4.64.
o-Uridine
TLC (Ethyl acetate/methanol 10:1): Rf = 0.27
1H NMR (250 MHz, D2O): N (ppm)= 3.40^4.07 (m, 3H, H-4P, H-
5Pa, H-5Pb), 4.90^5.80 (m, 4H, H-5, H-1P, H-2P, H-3P), 7.58^7.82 (m,
1H, H-6)
MALDI-MS: [M+Hþ] = 243.8
Methyl o-riboside
TLC (Ethyl acetate): Rf = 0.25
1H NMR (250 MHz, D2O): N (ppm)=3.32 (br.s, 3H, Me), 3.38^
4.01 (m, 3H, H-4P, H-5a, H-5Pb), 4.27^5.05 (m, 3H, H-1P, H-2P, H-3P)
MALDI-MS: [M+Naþ] = 184.7
r-UDP-GlcNAc
TLC (Ethyl acetate/methanol/water 3:2:1): Rf = 0.20
1H NMR (250 MHz, D2O): N (ppm)= 1.9 (s, 3H, Ac), 3.32^3.88
(m, 13H), 5,34 (dd, 1H, J10 0 ;20 0 =3 Hz, J10 0 ;P = 7 Hz, H-1Q), 5.76^5.81 (m,
2H, H-1P, H-5), 7,71 (d, 1H, J5;6 = 8 Hz, H-6)
31P NMR (243 MHz, D2O): N (ppm)=310.2 (d, 1P, J=21 Hz,
KP), 312.0 (d, 1P, J=17 Hz, LP)
2.3. Puri¢cation of UDP-GlcNAc 2-epimerase/ManNAc kinase from
Sf9 insect cells
UDP-GlcNAc 2-epimerase/ManNAc kinase from rat was recombi-
nantly expressed in Sf9 insect cells as described [18]. Cells (2U106)
were harvested and resuspended in 10 mM Na2HPO4, pH 7.5, 1 mM
ethylenediamine tetraacetic acid, 1 mM dithiothreitol (bu¡er A), 1 mM
phenylmethylsulfonyl £uoride. Cells were lysed by 20 strokes of a
syringe with a narrow needle, and the lysate was centrifuged at
100 000Ug for 30 min.
After centrifugation the supernatant was applied to a MonoQ HR
5/5 column (Pharmacia). The column was washed with 5 ml of bu¡er
A, and proteins were eluted by a linear gradient from 0 to 600 mM
NaCl in bu¡er A. Fractions of 1 ml were collected and checked by
UDP-GlcNAc 2-epimerase assay 1 as described below. The enzyme
eluted by about 300 mM NaCl. Fractions containing UDP-GlcNAc
2-epimerase/ManNAc kinase were applied to a Superdex 200 HR
10/30 gel ¢ltration column (Pharmacia). Proteins were eluted with
bu¡er A containing 100 mM NaCl. Fractions of 0.5 ml were collected,
monitored for activity by UDP-GlcNAc 2-epimerase assay 1, and for
purity by sodium dodecylsulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) using a MiniProteanII system (Bio-Rad, Munich, Ger-
many). UDP-GlcNAc 2-epimerase/ManNAc kinase eluted in fractions
corresponding to the expected size of 450 kDa [7] and showed a purity
of more than 95%.
2.4. Enzyme assays
UDP-GlcNAc 2-epimerase assay 1 contained 45 mM Na2HPO4,
pH 7.5, 10 mM MgCl2, 1 mM UDP-GlcNAc and variable amounts
of protein in a ¢nal volume of 200 Wl. The reaction was performed at
37‡C for 30 min and stopped by boiling for 1 min. The released
ManNAc was detected by the Morgan^Elson method [19]. In brief,
150 Wl of sample was mixed with 30 Wl of 0.8 M H2BO3, pH 9.1, and
boiled for 3 min. Then 800 Wl of DMAB solution (1% (w/v) 4-di-
methylamino benzaldehyde in acetic acid/1.25% 10 N HCl) was added
and incubated at 37‡C for 30 min. The absorbance was read at 578
nm.
UDP-GlcNAc 2-epimerase assay 2 was performed as described ear-
lier [7]. It contained 45 mM Na2HPO4, pH 7.5, 10 mM MgCl2, 1 mM
UDP-GlcNAc, 0.2 mM NADH, 2 mM phosphoenolpyruvate, 4 U (40
Wg) pyruvate kinase, 4 U (40 Wg) lactate dehydrogenase and variable
amounts of protein in a ¢nal volume of 800 Wl. The reaction was
performed at 37‡C and the decrease of NADH was continuously
monitored at 340 nm. Initial rates of enzyme activities were deter-
mined by applying tangents to the extinction curves.
The ManNAc kinase assay was performed as described earlier [7]. It
contained 60 mM Tris^HCl, pH 8.1, 10 mM MgCl2, 5 mM ManNAc,
10 mM ATP, 0.2 mM NADH, 2 mM phosphoenolpyruvate, 4 U (40
Wg) pyruvate kinase, 4 U (40 Wg) lactate dehydrogenase and variable
amounts of protein in a ¢nal volume of 800 Wl. The reaction was
performed at 37‡C and the decrease of NADH was continuously
monitored at 340 nm. Initial rates of enzyme activities were deter-
mined by applying tangents to the extinction curves.
The UDP-galactose 4-epimerase (UDP-Gal 4-epimerase) assay was
performed as described earlier [20]. It contained 100 mM glycine, pH
8.7, 5 mU UDP-glucose dehydrogenase, 0.125 mM UDP-Gal, 0.125
mM NADþ and variable amounts of yeast UDP-Gal 4-epimerase in
800 Wl. The reaction was performed at 37‡C for 20 min. The reaction
was stopped by boiling for 1 min and the resulting NADH was de-
tected at 340 nm.
2.5. Inhibition reactions
Stock solutions of inhibitors were prepared with a concentration of
100 mM in water. Puri¢ed UDP-GlcNAc 2-epimerase/ManNAc ki-
nase (2 Wg) was incubated with various concentrations of inhibitors
for the indicated periods. Enzyme activities were determined as de-
scribed above. Subunit crosslinking by o-UDP-GlcNAc was moni-
tored by applying the samples to reducing SDS-PAGE and staining
the gels with silver.
Fig. 1. Structure and synthesis of o-UDP-GlcNAc (2) and r-UDP-
GlcNAc (3). The compounds were synthesized from UDP-GlcNAc
(1). First, a periodate-oxidation resulted in formation of (2), then
borohydride reduction of (2) formed (3). Synthesis was performed
as described in detail in Section 2.
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UDP-Gal 4-epimerase stock solution (5 Wg/ml) was diluted 1:10 in
phosphate-bu¡ered saline; 0.05 Wg was incubated with the indicated
amounts of inhibitors, and enzyme activity was determined as de-
scribed above.
3. Results and discussion
3.1. Inhibition of UDP-GlcNAc 2-epimerase activity by
o-UDP-GlcNAc and related compounds
Prehm [17] reported the inhibition of human hyaluronate
synthase by o-UDP-GlcNAc. An inhibitory e¡ect of o-UDP-
GlcNAc on the activity of methylcoenzyme M methylreduc-
tase from Methanobacterium thermoautotrophicum, catalyzing
the reduction of methylcoenzyme M to methane and co-
enzyme M (2-mercaptoethanesulfonic acid) with UDP-
GlcNAc as part of an essential cofactor, was also found
[21]. It was concluded that the inhibitor bound to UDP-
GlcNAc binding sites within both enzymes. Periodate oxida-
tion of UDP-GlcNAc led to a cleavage of the ribose ring
between C2 and C3 and the formation of two adjacent alde-
hyde groups (Fig. 1). We therefore investigated whether
o-UDP-GlcNAc was also able to inhibit the activity of
UDP-GlcNAc 2-epimerase. o-UDP-GlcNAc was ¢rst tested
over a wide range of concentrations and incubation times.
Inhibitor concentrations in the 100 WM range and incubation
times up to 1 h resulted in e⁄cient inhibition of UDP-GlcNAc
2-epimerase (data not shown). The inhibition e⁄ciency was
therefore in the same range as that for hyaluronate synthase
and methylcoenzyme M methylreductase [17,21].
For more detailed information on the speci¢city and e⁄-
ciency of the inhibition of UDP-GlcNAc 2-epimerase activity,
we compared o-UDP-GlcNAc with several periodate-oxidized
diphosphonucleotides, uridine and methyl riboside (Fig. 2A).
o-UDP-GlcNAc appeared to be the most e¡ective inhibitor of
the tested compounds. After 30 min incubation, 50 WM
o-UDP-GlcNAc inhibited by about 70%, while at 250 WM
the inhibitor decreased enzyme activity to less than 10%. An
e¡ective enzyme inhibition was also found using o-UDP and
o-ADP. A more signi¢cant result showing the speci¢city of
o-UDP-GlcNAc was obtained at an inhibitor concentration of
300 WM when the time course of inhibition was monitored
continuously by assay 2 (Fig. 3A). o-UDP-GlcNAc was the
most e¡ective inhibitor under these conditions. o-UDP and
o-ADP again showed a similar e¡ect on UDP-GlcNAc 2-epi-
merase activity. o-GDP, o-uridine and methyl o-riboside had
almost no e¡ect on the enzyme activity.
The overall inhibition e⁄ciency during the continuous assay
2 was lower compared to that observed when using the non-
continuous assay 1. The di¡erence between the two assays was
the addition of a larger quantity of protein (about 80 Wg of
pyruvate kinase and lactate dehydrogenase) in the continuous
assay, which was 40 times greater than the quantity of UDP-
GlcNAc 2-epimerase. Under these conditions most of the in-
hibitors were probably inactivated by an unspeci¢c reaction of
the aldehyde groups of the inhibitors with free amino groups
of the proteins (for details see Section 3.3). On the other hand,
inhibition of UDP-GlcNAc 2-epimerase activity by o-UDP-
GlcNAc, o-UDP and o-ADP showed the high speci¢city of
these inhibitors for the enzyme. o-UDP-GlcNAc seemed to be
bound rapidly and tightly by the active site of UDP-GlcNAc
2-epimerase and was therefore able to act as an inhibitor. It is
known that UDP can also bind to the active site of the en-
zyme, because it stabilizes the hexameric state [7], and a re-
action mechanism involving an exchange of UDP and UDP-
GlcNAc has been proposed. It was therefore also suggested
that o-UDP binds to the active site of UDP-GlcNAc 2-epi-
merase.
It should be noted that o-ADP also inhibited UDP-GlcNAc
2-epimerase. o-ADP, like o-UDP, may bind to the active site
of UDP-GlcNAc 2-epimerase. Alternatively, it may act on the
ATP binding site of ManNAc kinase, which is fused to UDP-
Fig. 2. Inhibition of UDP-GlcNAc 2-epimerase activity (A) and
ManNAc kinase activity (B) by di¡erent concentrations of o-UDP-
GlcNAc and derivatives. Puri¢ed UDP-GlcNAc 2-epimerase/Man-
NAc kinase was incubated with the indicated concentrations of in-
hibitors for 30 min. Enzyme activities were determined with UDP-
GlcNAc 2-epimerase assay 1 and ManNAc kinase assay as de-
scribed in Section 2. Values are means of two independent experi-
ments.
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GlcNAc 2-epimerase in vivo, but which has been shown to
work independently [18]. Nevertheless, an allosteric e¡ect on
UDP-GlcNAc 2-epimerase activity by binding of o-ADP to
the ManNAc kinase domain remained a possibility. Therefore
the panel of inhibitors was also tested for inhibition of Man-
NAc kinase activity. For an equivalent inhibition of the two
enzyme activities, inhibitor concentrations were 40-fold higher
for ManNAc kinase than for UDP-GlcNAc 2-epimerase (Fig.
2B). Under conditions used for an e⁄cient inhibition of UDP-
GlcNAc 2-epimerase, almost no inhibition of ManNAc kinase
was observed (Fig. 3B). o-ADP was still the most e¡ective
inhibitor of ManNAc kinase, suggesting a binding to the
ATP binding site of the enzyme. This was con¢rmed by the
inhibition e⁄ciency of the other o-modi¢ed compounds used,
which corresponded to their structural similarity to o-ADP.
From these results it is concluded that the inhibition of UDP-
GlcNAc 2-epimerase and ManNAc kinase occurred by inde-
pendent binding of the respective inhibitor to the two active
sites of the bifunctional enzyme. Therefore the e⁄cient inhi-
bition of UDP-GlcNAc 2-epimerase by o-ADP was most
likely due to the structural similarity to o-UDP and not to
an allosteric e¡ect via the ATP binding site.
3.2. Inhibition of UDP-Glc 4-epimerase by o-UDP-GlcNAc and
o-UDP
In order to further evaluate the speci¢city of o-UDP-
GlcNAc and o-UDP in the inhibition of UDP-GlcNAc 2-epi-
merase, the compounds were also tested using commercially
available UDP-Gal 4-epimerase. UDP-Gal 4-epimerase cata-
lyzes the interconversion of UDP-Gal and UDP-Glc and it is
suggested that at least the mammalian UDP-Gal 4-epimerases
[22] also catalyze the interconversion of UDP-GlcNAc and
UDP-GalNAc. UDP-Gal 4-epimerase was inhibited by
o-UDP-GlcNAc and o-UDP (Fig. 4). o-UDP-GlcNAc was
more e¡ective than o-UDP, indicating that the nucleotide
sugar had a higher a⁄nity to the enzyme than the correspond-
ing nucleotide. Nevertheless, an about 100-fold higher concen-
tration was necessary to show a comparable e¡ect on UDP-
GlcNAc 2-epimerase. Therefore it can be concluded that
o-UDP-GlcNAc has a much higher a⁄nity to UDP-GlcNAc
2-epimerase and other enzymes with a speci¢c UDP-GlcNAc
binding site [17,21], thus making it possible to avoid numer-
ous side e¡ects when appropriate concentrations are applied
to cells.
Fig. 4. Inhibition of UDP-Gal 4-epimerase and UDP-GlcNAc 2-epi-
merase by o-UDP-GlcNAc and o-UDP. UDP-Gal 4-epimerase and
puri¢ed UDP-GlcNAc 2-epimerase/ManNAc kinase were incubated
with the indicated concentrations of o-UDP-GlcNAc and o-UDP
for 30 min. Enzyme activities were determined with UDP-GlcNAc
2-epimerase assay 1 and the UDP-Gal 4-epimerase assay as de-
scribed in Section 2. Values are means of two independent experi-
ments.
Fig. 3. Time dependence of the inhibition of UDP-GlcNAc 2-epi-
merase activity (A) and ManNAc kinase activity (B) by o-UDP-
GlcNAc and derivatives. Puri¢ed UDP-GlcNAc 2-epimerase/Man-
NAc kinase was incubated with 300 WM inhibitor for the indicated
periods of time. Enzyme activities were determined with UDP-
GlcNAc 2-epimerase assay 2 and the ManNAc kinase assay as de-
scribed in Section 2. Values are means of two independent experi-
ments.
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3.3. Characterization of the inhibitory features of
o-UDP-GlcNAc
Periodate oxidation of UDP-GlcNAc leads to the forma-
tion of two aldehyde groups at the ribose of the sugar nucle-
otide. These aldehydes may react preferentially with the pri-
mary amine groups of lysine residues of proteins. This would
lead to a covalent binding of o-UDP-GlcNAc in the substrate
binding site of UDP-GlcNAc 2-epimerase, thereby blocking
the active site for further reactions. In order to determine if
o-UDP-GlcNAc acted as an irreversible or a competitive in-
hibitor on UDP-GlcNAc 2-epimerase, we tried to in£uence
the inhibition with the natural substrate UDP-GlcNAc.
When a mixture of UDP-GlcNAc and o-UDP-GlcNAc was
applied to UDP-GlcNAc 2-epimerase the inhibition of enzyme
activity was reduced, but when the enzyme was pretreated
with o-UDP-GlcNAc, the subsequent addition of UDP-
GlcNAc did not restore epimerase activity (data not shown).
This indicates that o-UDP-GlcNAc bound covalently to ami-
no acid residues in the active site of UDP-GlcNAc 2-epimer-
ase, causing an irreversible inhibition, which was not compet-
itive.
A further control was performed with r-UDP-GlcNAc,
which was synthesized by reduction of o-UDP-GlcNAc with
sodium borohydride (Fig. 1). UDP-GlcNAc 2-epimerase was
treated with 300 WM o-UDP-GlcNAc and r-UDP-GlcNAc,
respectively, under the conditions of assay 2. This resulted
in an inhibition of 93% by o-UDP-GlcNAc, but only 16%
by r-UDP-GlcNAc. r-UDP-GlcNAc behaved as a competitive
inhibitor, since the inhibitory e¡ect could be overcome by an
excess of UDP-GlcNAc (data not shown). In contrast, the
high inhibitory e⁄ciency of o-UDP-GlcNAc was due to the
reactivity of its aldehyde groups. Therefore the irreversible
inhibition of UDP-GlcNAc 2-epimerase by o-UDP-GlcNAc
or derivatives seems to be a more promising basis for creating
a potent inhibitor than using a competitive inhibitor. o-UDP-
GlcNAc contains a dialdehyde group which is similar to the
structure of glutardialdehyde, a well known reagent for cross-
linking of proteins [23]. We therefore tested the ability of
o-UDP-GlcNAc to act as a crosslinker for UDP-GlcNAc
2-epimerase/ManNAc kinase. In its fully active state UDP-
GlcNAc 2-epimerase/ManNAc kinase is a hexameric enzyme.
Storage of the enzyme in the absence of UDP-GlcNAc or
UDP results in decay to a dimer with loss of epimerase activ-
ity [7], but surprisingly the enzyme still displays ManNAc
kinase activity, showing that UDP-GlcNAc 2-epimerase is
retained independently of the fused ManNAc kinase domain.
Furthermore, point mutations of distinct amino acids in the
epimerase domain resulted in formation of epimerase-inactive,
but kinase-active trimers [18]. UDP-GlcNAc 2-epimerase/
ManNAc kinase was treated with 2.5 mM o-UDP-GlcNAc
and the time course of crosslinking was monitored by dena-
turing and reducing SDS^PAGE (Fig. 5). The control sample
showed only monomeric protein (75 kDa), but as early as
5 min after treatment a trimeric form emerged. The reaction
then progresses via the formation of an intermediate pentam-
er, until ¢nally a hexameric, crosslinked protein was observed.
The slight shift in molecular masses of the proteins was prob-
ably due to the binding of large amounts of negatively
charged o-UDP-GlcNAc molecules to the protein, leading to
a lower apparent molecular mass in SDS^PAGE. Crosslinking
of UDP-GlcNAc 2-epimerase with disuccinimidyl suberate,
another often used protein crosslinker [23], con¢rmed the for-
mation ¢rstly of trimers and ¢nally of hexamers, but without
a shift in molecular mass (data not shown). These results
indicate that o-UDP-GlcNAc is able to form covalent bonds
to amino acid residues of UDP-GlcNAc 2-epimerase.
When treating UDP-GlcNAc 2-epimerase/ManNAc kinase
with 2.5 mM o-UDP-GlcNAc, as used above, irreversible in-
hibition of both enzyme activities was also observed. There-
fore the inhibition may be due to a covalent binding of the
aldehyde groups of o-UDP-GlcNAc in the active sites of the
enzyme. On the other hand, the time course of inhibition of
UDP-GlcNAc 2-epimerase activity and of ManNAc kinase
activity is not consistent with the time course of the formation
of trimers and higher aggregates by crosslinking (Fig. 3 and
not shown). Furthermore, crosslinking with o-UDP and
o-ADP gave very similar crosslinking results compared to
o-UDP-GlcNAc. This indicates that the site of crosslinking
is not within the active sites of the enzyme and an independent
trimerization site with vicinal reactive amino acids on two
separate subunits is postulated. Interestingly, the formation
of dimers was not observed, but a formation of dimers of
trimers, resulting in hexamers. This suggests the existence of
an independent dimerization site, whose amino acids react
more slowly with crosslinking agents. Knowledge about the
three-dimensional structure of the enzyme is needed to verify
this model.
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